Cardiorenal benefits of sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus

钠-葡萄糖协同转运蛋白 2 抑制对 1 型糖尿病的心肾益处

• 批准号: 467193
• 负责人: Kugathasan Luxcia
• 金额: $ 1.27万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-12-01 至 2022-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=467193&lang=en
• 关键词: Biomarkers; Cardiorenal Protection; Cardiovascular Disease; Chronic Kidney Disease; Dapa-Sweet Trial; Diabetes Longevity Study; Diabetes Mellitus; Diabetic Kidney Disease; Sglt2 Inhibitors; Type 1 Diabetes

Diabetes mellitus is one of the fastest growing public health crises worldwide and accounts for 6% of global prevalence. Chronic high blood glucose, a hallmark of diabetes, stems from impaired insulin release or action, defined as type 1 diabetes (T1D) or

糖尿病是全球增长最快的公共卫生危机之一，占全球患病率的6%。慢性高血糖是糖尿病的一个标志，源于胰岛素释放或作用受损，定义为1型糖尿病(T1D)或